Ronald N. Marcus, MD

  • 17Articles
  • 54.3KReads
  • 2006–2025Active
  • 65Collaborators
  • 1.2KCitations

About

Ronald N. Marcus, MD, is affiliated with Bristol Myers Squibb in Princeton, New Jersey. He has contributed to Psychiatrist.com since 2006, authoring 17 articles on topics including schizophrenia, depression, bipolar disorder, child and adolescent psychiatry, and metabolic disorders. Frequent collaborators include Robert D. McQuade, William H. Carson, Berit X. Carlson, Raymond Sanchez, and Robert M. Berman.

Publications

JCP
Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia
Original Research

Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.
, , , et al
JCP
Original Research

A Randomized Controlled Trial Investigating the Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder

January 15, 2014

, , , et al
JCP
Article

Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study

July 26, 2011

, , , et al
PCC
Original Research

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)

December 17, 2009

, , , et al
JCP
Original Research

Adjunctive Aripiprazole in Major Depressive Disorder: Analysis of Efficacy and Safety in Patients With Anxious and Atypical Features

December 31, 2008

, , , et al
PCC
Original Research

Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies

December 15, 2008

, , , et al
JCP
Original Research

The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia: A Pooled Post Hoc Analysis From 5 Short-Term Studies

December 2, 2008

, , , et al
JCP
Original Research

A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine

July 31, 2008

, , , et al
JCP
Letter to the Editor

Reply to Aripiprazole and Perphenazine: No Difference

November 15, 2007

, , , et al
JCP
Original Research

Comparison of Metabolic Syndrome Incidence Among Schizophrenia Patients Treated With Aripiprazole Versus Olanzapine or Placebo

October 15, 2007

, , , et al
JCP
Original Research

Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo

October 15, 2007

, , , et al
JCP
Original Research

Antimanic Response to Aripiprazole in Bipolar I Disorder Patients Is Independent of the Agitation Level at Baseline

September 17, 2007

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe